The intended audience for this activity are neurology, neuromuscular, neuroimmunology, and neuro-ophthalmology specialists, along with advanced practice neurology practitioners, such as neurology NPs, neurology PAs, and clinical pharmacists.
The treatment paradigm for generalized myasthenia gravis (gMG) is changing rapidly with the availability of new antibody tests and targeted treatment options. The treatment landscape for gMG is shifting from reliance on nonspecific immunosuppressants to personalized targeted approaches that address the underlying pathophysiology and achieve disease remission. More than ever, clinicians must engage their patients with gMG in shared decision-making to ensure treatment selection aligns with patient characteristics, preferences, and goals.
In this module, join expert neurologists as they discuss the most appropriate and evidence-based treatment selection for a MuSK+ patient. This case will help review the burden of disease and unmet needs faced by patients with gMG, while enhancing clinicians’ ability to identify patient preferences and goals and encourage shared decision-making.
Upon completion of this activity, participants should be better able to: